Sophiris Bio Inc (NASDAQ:SPHS) shares hit a new 52-week high on Tuesday . The company traded as high as $4.45 and last traded at $3.97, with a volume of 16,227,074 shares changing hands. The stock had previously closed at $3.12.

A number of analysts recently commented on the company. Echelon Wealth Partners reiterated a “buy” rating and set a $5.00 price objective on shares of Sophiris Bio in a research report on Friday, June 10th. Maxim Group reiterated a “buy” rating and set a $4.00 price objective on shares of Sophiris Bio in a research report on Friday, June 10th.

The company’s market capitalization is $83.26 million. The company has a 50 day moving average price of $1.99 and a 200-day moving average price of $1.66.

Sophiris Bio (NASDAQ:SPHS) last released its quarterly earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.06. On average, equities analysts expect that Sophiris Bio Inc will post ($0.73) earnings per share for the current year.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.